Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Depreciation & Amortization (CF) (2020 - 2025)

Arcutis Biotherapeutics has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $153000.0 for Q1 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $153000.0 for Q1 2025, down 10.0% from a year ago — trailing twelve months through Dec 2025 was $153000.0 (down 76.09% YoY), and the annual figure for FY2024 was $640000.0, down 20.0%.
  • Depreciation & Amortization (CF) for Q1 2025 was $153000.0 at Arcutis Biotherapeutics, up from $145000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for ARQT hit a ceiling of $227000.0 in Q4 2023 and a floor of $98000.0 in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $160000.0 (2022), compared with a mean of $159705.9.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 420.0% in 2021 and later plummeted 36.12% in 2024.
  • Arcutis Biotherapeutics' Depreciation & Amortization (CF) stood at $182000.0 in 2021, then dropped by 12.09% to $160000.0 in 2022, then skyrocketed by 41.88% to $227000.0 in 2023, then tumbled by 36.12% to $145000.0 in 2024, then grew by 5.52% to $153000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $153000.0 (Q1 2025), $145000.0 (Q4 2024), and $161000.0 (Q3 2024) per Business Quant data.